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Transient SIV viremia after experimental SIV challenge has been documented. Whether SIV persists in these transiently viremic
macaques remains unclear. In the present study, we applied a sensitive PCR and found persistent low levels of SIVmne infection (LLSI)
(range: 0.1–5.3 SIV DNA copies/106 PBMC) in seven macaques that were transiently positive by conventional assays, which was 102- to
106-fold less than those of SIVmne infected monkeys with typical disease progression. SIV envelope V1 sequences remained homogeneous
in these macaques for the 6-year study period, with a mean evolution rate of 0.005% per site per year, which was not different from zero (P =
0.612) and significantly lower than that (0.56–1.18%) in macaques with progressive infection of SIVmne. LLSI macaques have remained
free from SIV-associated illness, and are still alive 10 years after virus inoculation. Understanding the mechanisms underlying this outcome
may provide valuable insight into therapy and vaccine development.
D 2004 Elsevier Inc. All rights reserved.Keywords: SIV; Macaques; Transient viremia; Low level of infection; PCR; Evolution; Disease progression
Introduction (Bakshi et al., 1995; Bryson et al., 1995; Roques et al.,Infection with human immunodeficiency virus type 1
(HIV-1) results in a variety of clinical outcomes. The
majority of HIV-1-infected individuals progress to AIDS
over 5–10 years; some progress rapidly to AIDS (termed
rapid progressors), others progress to AIDS at slower rates
(slower progressors). A small number of HIV-1-infected
individuals, known as long-term non-progressors (LTNP),
remain clinically healthy for more than a decade after
infection (Buchbinder et al., 1994; Cao et al., 1995; Deacon
et al., 1995; Pantaleo et al., 1995). Transient infection0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.03.004
$ Supplementary data for this article are available on ScienceDirect.
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E-mail address: tzhu@u.washington.edu (T. Zhu).1995) or silent infection (Haseltine, 1989; Imagawa et al.,
1989) with HIV-1 was proposed, although this pattern of
HIV-1 infection has not been unambiguously confirmed by
genetic analyses of the virus in these exposed-seronegative
(ES) individuals (McClure et al., 1995). Furthermore, ex-
tensive genetic analyses of HIV-1 in the suspected transient
infection in infants indicate documented cases of transient
infection are cases of mislabeling of specimens or their
contamination in the laboratories (Frenkel et al., 1998).
Nevertheless, detection of cellular and mucosal humoral
immune responses to HIV-1 suggests that some ES had been
infected earlier, or that they have a silent infection or had
virus cleared (Gibbons et al., 1990; Goh et al., 1999; Pinto
et al., 1995; Rowland-Jones et al., 1993, 1995). A most
recent study showed that in rare ES individuals, HIV-1
provirus DNA actually persisted throughout the study peri-
od of 6 years, but largely in resting CD4+ T cells, and at
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million cells) that are well below the detection limit of
conventional assays (Zhu et al., 2003).
Simian immunodeficiency virus (SIV) infection of mac-
aques is a model commonly used for studying HIV-1
pathogenesis. The three patterns of infection with rapid,
slow, or no disease progression described above in HIV-1
infection have been reported in macaques infected with SIV
(Daniel et al., 1987; Letvin and King, 1990). In addition,
transient SIV viremia was found in monkeys following
inoculation of low doses of pathogenic SIVmac or SIVmne
by the intravaginal (Miller et al., 1994), intrarectal (Pauza et
al., 1993; Polacino et al., 1999a, 1999b; Trivedi et al., 1996),
oral (van Rompay et al., 1998), or intravenous (Dittmar et al.,
1995; Polacino et al., 1999a, 1999b) route. In these studies,
proviral DNA could be detected by conventional assays in
peripheral blood mononuclear cells (PBMCs) in the absence
of virus culture isolation for prolonged periods following
inoculation (Pauza et al., 1993) or only during the early stage
of infection (Dittmar et al., 1995; Miller et al., 1994). In
addition, occult systemic infection in some of these mac-
aques with transient viremia was proposed based on the
detection of persistent SIV-specific CD4+ T-cell proliferative
responses and SIV provirus in PBMC and tissues at necropsy
(McChesney et al., 1998). However, it was unclear whether
SIV existed persistently in vivo in these animals, because
longitudinal samples and sensitive assays that were able to
detect and confirm low levels of SIV infection were unavail-
able. In the present study, we applied a sensitive PCR and
performed extensive analyses for SIVmne sequences of the
extracellular envelope (env) protein, using procedures paral-
lel to those described previously for HIV-1 (Zhu et al., 2003),
and found evidence for persistence of low levels of SIVmne
infection (LLSI) in seven macaques that were previously
found transiently viremic by conventional assays and that
have remained alive and disease-free for up to 10 years.Results
Study subjects
Animals used in this study were selected from a group of
97 cynomolgus macaques (Macaca fascicularis) used in a
series of previously reported vaccine studies (Polacino et al.,
1999a, 1999b, 1999c). These include naı¨ve unimmunized
animals as well as animals immunized by various combi-
nations of recombinant vaccinia viruses and subunit proteins
composed of the envelope and core antigens of SIVmne. All
animals were challenged with SIVmne E11S (a virus
derived from a single-cell clone of SIVmne-infected HuT
78 cells) (Benveniste et al., 1990) or uncloned SIVmne, by
intravenous (IV) or intrarectal (IR) routes. The challenge
doses used were 10–100 animal infectious doses (AID) for
IV inoculations, or 2–20 AID for IR inoculations (Polacino
et al., 1999a, 1999b, 1999c). Virologic and serologic statusof these animals were determined by conventional assays,
including semiquantitative PCR for provirus DNA, reverse
transcription PCR (RT-PCR) for plasma viral RNA, virus
isolation from peripheral blood mononuclear cells (PBMCs)
by co-culture, SIV-specific antibodies by enzyme-linked
immunosorbent assay (ELISA), Western blot and serum
neutralization assays, all as reported previously (Polacino
et al., 1999a, 1999b, 1999c). Seven of 63 immunized and 3
of 34 nonimmunized control macaques were found after
challenge to be transiently virus positive by standard PCR
and co-culture assays (Polacino et al., 1999a, 1999b). Five
immunized (Groups 1 and 3 in Table 1) and all three control
(Group 2 in Table 1) macaques with transient viremia were
available for the present study.
Of the five immunized macaques studied, four animals
(Group 1 in Table 1) remained virus-negative by standard
virologic and clinical assessments (Polacino et al., 1999a,
1999b). Two immunized animals (#91263 and #91250 of
Group 1 in Table 1) were initially challenged with E11S by
intravenous (IV) route and were followed for 2 years with no
evidence of SIV infection by PBMC isolation and PCR at
multiple time points before re-challenged intravenously with
uncloned SIVmne (Polacino et al., 1999a, 1999b, 1999c).
Macaque 91278 had a positive PCR on PBMC at week 2
post virus re-challenge, then had remained SIV negative at
all time points tested (Kent et al., 1996; Polacino et al.,
1999c). Similarly, macaque 91263 was SIV negative at
multiple time points tested for virus isolation from PBMC
and PCR analyses of both PBMC and lymph node, except
one positive PCR on PBMC at week 20 post re-challenge
(Polacino et al., 1999a). One immunized macaque chal-
lenged with E11S (#91272 of Group 3 in Table 1) was
initially viremic (positive PCR on PBMC DNA at week 2
postchallenge), but became SIV negative for 41 weeks by
conventional PBMC PCR, with only occasionally detectable
viral sequences in lymph node DNA by PCR (Polacino et al.,
1999a). However, this animal became viremic again 57
weeks postchallenge, followed by rapidly declining CD4+
T cell counts, resulting in simian AIDS at week 99 and
euthanasia at week 101 (Polacino et al., 1999a).
All three control macaques exhibiting transient viremia
were challenged intrarectally (IR) with uncloned SIVmne.
One animal (#92175 of Group 2 in Table 1) was first
challenged with E11S by IV route, held for 1 year with
negative results on all testing at multiple time points
(Polacino et al., 1999a, 1999b, 1999c), and was re-chal-
lenged with uncloned SIVmne. All three IR-challenged
control animals, following initial viremia, remained virus-
negative by conventional assays as described above during
the study period (Polacino et al., 1999a, 1999b, 1999c).
With the exception of macaque #91272 described above and
macaque #91263, which died of unrelated cause, all immu-
nized and control macaques in this study have had normal
CD4+ T cells counts, and have remained healthy without
any SIV associated opportunistic infections for up to
10 years.
Table 1
Characteristics of transiently SIV-positive macaques
Macaque Challenge SIV Route Sampling weeks
postchallenge
SIV DNA copies/
106 PBMCa
Sero-status
by ELISAb
NAb against
SIVmnec
Group 1. Transiently SIV-positive immunized macaques
90114 E11S IV 0 ND POS <20
2 6.10 POS ND
32 2.11 POS ND
52 2.79 POS ND
92 0.65 ND ND
151 1.87 ND ND
228 1.50 ND ND
246 0.51 ND ND
322 0.21 ND ND
91250 E11S/uncloned IV/IVd 0 ND POS 142
mne 2 21.50 POS ND
4 31.60 POS ND
6 23.80 POS ND
162 1.76 ND ND
173 1.42 ND ND
235 2.80 ND ND
91263 E11S/uncloned IV/IVd 0 ND POS 38
mne 2 15.10 POS ND
4 4.30 POS ND
20 5.30 POS ND
118 1.30 ND ND
200 0.10 ND ND
91278 E11S IV 0 ND POS 20
2 3.90 POS ND
6 – POS ND
12 – POS ND
52 – POS ND
183 – ND ND
270 – ND ND
Group 2. Transiently SIV-positive unimmunized macaques
93206 uncloned mne IR 0 ND NEG <20
2 ND NEG ND
4 31.51 NEG ND
6 ND NEG ND
109 3.52 NEG ND
152 2.16 NEG ND
177 1.32 NEG ND
187 3.32 NEG ND
202 0.34 NEG ND
210 0.12 NEG ND
92175 E11S/uncloned IV/IRd 0 ND NEG <20
mne 2 ND NEG ND
4 27.91 NEG ND
55 2.21 NEG ND
100 1.75 NEG ND
109 0.81 NEG ND
178 2.34 NEG ND
210 0.32 NEG ND
93080 uncloned mne IR 0 ND NEG <20
2 333.63 NEG ND
109 4.51 NEG ND
152 2.35 NEG ND
177 0.41 POS ND
187 0.82 NEG ND
202 1.42 NEG ND
210 0.89 NEG ND
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Fig. 1. Comparison of the levels of cell-associated SIV DNA in peripheral
blood lymphocytes in LLSI macaques (red square, n = 7), macaque with
delayed disease progression (black diamond, n = 1), and immunized (blue
circle, n = 10) or unimmunized (green triangle, n = 13) macaques with
normal disease progression (Polacino et al., 1999a, 1999b, 1999c). All
macaques with normal disease progression died within 2 years post-
challenge (Polacino et al., 1999a, 1999b, 1999c). Nonlinear regression
curves depict the trend in viral load for each group by using GraphPad
Prism version 3.00 (GraphPad Software, Inc., San Diego, CA).
Table 1 (continued )
Macaque Challenge SIV Route Sampling weeks
postchallenge
SIV DNA copies/
106 PBMCa
Sero-status
by ELISAb
NAb against
SIVmnec
Group 3. Immunized macaque with delayed progression of SIV infection
91272 E11S IV 0 ND POS 52
2 47.81 POS ND
4 21.3 POS ND
44 45.51 POS ND
99 7691.01 POS ND
a SIV copy numbers were calculated based on limiting dilution PCR on each sample (Zhu et al., 2002, 2003) and a computer program, ‘‘QUALITY’’, as
described previously (Rodrigo et al., 1997). SIV DNAwas undetectable in animal D (#91278) at multiple time points between 6 and 270 weeks postchallenge
within a context of DNA from 10 million PBMC. ND, not done.
b SIV-specific sero-status was determined by enzyme-linked immunosorbent assay (ELISA) as published previously (Polacino et al., 1999a, 1999b, 1999c).
The starting dilution of test sera was 1:100. Sample was considered seropositive if the optical density (OD) reading in ELISAwas greater than the cut-off value
(0.349 in these studies), which was defined as 3-fold greater than the average OD obtained with negative control sera. POS, positive; NEG, negative.
c Neutralization antibody (Nab) was only tested at day of challenge (week 0) (Polacino et al., 1999a, 1999b, 1999c). Two-fold serum dilutions (heat inactivated
at 56 jC for 30 min) were done in 96-well plates. The neutralization titer is expressed as the serum dilution that inhibits 50% of SIVmne-induced cytopathic
effect in CEM  174 cells or 90% syncytium formation by SIVmac251-infected HuT78 cells (Polacino et al., 1999a, 1999b, 1999c).
d Macaques were challenged with E11S by intravenous (IV) route first, and had remained negative for PBMC isolation and PCR at multiple time points for
more than 1 year when they were re-challenged with uncloned SIVmne via IV (#91250 and #91263) or intrarectal (IR, #92175) route as described previously
(Polacino et al., 1999a, 1999b, 1999c). The sampling weeks for these animals were post re-challenge.
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By performing hundreds of independent limiting dilution
PCR on each sample with similar procedures described
previously (Zhu et al., 2003), we found that SIV DNA
persisted at low levels in all studied macaques that were
previously found transiently virus positive or vaccine-pro-
tected by conventional assays. SIV provirus DNA was
detected at week 2 in macaque 91278, but was undetectable
within a context of DNA from 10 million PBMC available
at multiple time points between 6 and 270 weeks postchal-
lenge. Thus, the macaque appeared a true case of transient
viremia. SIV provirus levels in other 7 LLSI macaques were
2–5 logs lower than those in SIVmne-infected macaques
with disease progression (P < 0.0001) (Fig. 1 and Table 2)
(Polacino et al., 1999a, 1999b, 1999c). SIV DNA copy
numbers were relatively higher in the first 6 weeks, and
were on average 2 logs lower than those in macaques with
progressive infection (Table 2). Then, SIV proviral DNA
declined and persisted at low levels in both unimmunized
and vaccinated LLSI animals. These numbers are lower than
the detection limit of conventional assays used previously
(Kent et al., 1996; Polacino et al., 1999c), and were orders
of magnitudes (102- to 106-fold) less than those of SIV-
infected monkeys with typical disease progression (Fig. 1
and Table 2) (Polacino et al., 1999a, 1999b, 1999c).
Sequence variation in challenge virus
Sequence variation in SIV such as SIVmne, SIVmac,
and SIVsm is observed in the V1 region of env during
progression to simian AIDS (Burns and Desrosiers, 1991;
Johnson et al., 1991; Overbaugh and Rudensey, 1992;
Overbaugh et al., 1991), suggesting that these envelope
changes are selected in the context of different infectingviral strains and in different macaque host species. The V1
region of env also encodes sequences that comprise part of
the determinants for neutralization, syncytium formation,
and macrophage tropism for SIVmne (Rudensey et al.,
1998). We therefore examined V1 sequences of SIVmne to
assess the extent of viral variation over time in peripheral
Table 2
Analysis of SIV DNA copies in macaques with persistently low levels of
SIV infection (LLSI)
Animal SIV DNA copies/106 PBMC (mean F SE)
All time points Weeks 2–6 After week 6
LLSIa 10.66 F 5.50 49.93 F 35.12 1.69 F 0.27
Immunized (n = 3) 6.43 F 2.03 13.95 F 3.80 1.68 F 0.25
Unimmunized (n = 3) 31.47 F 25.35 131 F 101 1.72 F 0.38
Progressorb 5693 F 892 4782 F 1456 6125 F 1102
Immunized (n = 10) 4555 F 737 2053 F 1021 5487 F 1086
Unimmunized (n = 13) 7959 F 1291 10675 F 4291 6382 F 1121
a SIV DNA copy numbers in LLSI were calculated based on limiting
dilution PCR on each sample (Zhu et al., 2002, 2003) and a computer
program, ‘‘QUALITY’’, as described previously (Rodrigo et al., 1997).
b SIV DNA copy numbers were calculated by a standard DNA PCR as
published previously (Polacino et al., 1999a, 1999b, 1999c).
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cloning and sequencing of two challenge virus stocks.
The V1 sequences of the biologically cloned challenge
virus, E11S, were highly homogeneous. However, the
uncloned challenge virus contain a major population
(86%) of E11S-like virus (or clone MNE.1-like in Fig.
2A) and two minor populations of V1-distinct variants
(10% of clone MNE.19-like and 4% of clone MNE.10-like
sequences) that contain significant mutations in the C-
terminal portion of V1 as compared to the major E11S-like
sequences (Fig. 2A).
Sequence diversity in vaccinated LLSI macaques
We then examined SIVmne V1 sequences in longitudinal
PBMC ranging from weeks 2–322 post viral challenge in
four vaccinated LLSI macaques. Both macaques 90114 and
91278 were inoculated with biological clone E11S, whereas
macaques 91263 and 91250 were challenged with uncloned
SIVmne. As expected, E11S-like variants were found in
macaques 90114 and 91278 (Fig. 2B). However, of the two
macaques challenged with uncloned SIVmne, one (#91263)
was infected with E11S-like major variants and another
(#91250) was infected with the V1-distinct minor variants.
SIV V1 sequences remained homogeneous in all these
macaques for up to 6 years, no matter whether they were
infected with the minor variants or with the major variants.
The only stable change was a single nucleotide mutation
that resulted in an alanine to threonine substitution at
position 59 of the sequenced region, which was seen in
both provirus in PBMC and viral RNA in peripheral blood
plasma at week 235 post infection in macaque 91250 (Fig.
2B). The rates of SIV sequence evolution in macaques
90114 and 91263 were not significantly different from zero
(Table 3). SIV sequences in macaque 91250 evolved sig-
nificantly (Table 3), but at a evolutionary rate that was 10- to
20-fold lower than those in macaques with progressive
SIVmne infection (0.56%/site/year for V1–V4 region)
(Overbaugh et al., 1991) or delayed disease progression
(1.178% in macaque 91272, Table 3). Furthermore, theaverage evolutionary rate of SIV V1 sequences in these
vaccinated LLSI macaques was 0.013%/site/year, which,
again, was not significantly different from zero (P = 0.112).
These results suggest an essential lack of virus evolution in
LLSI macaques.
Sequence diversity in unimmunized LLSI macaques
Three unimmunized LLSI macaques were inoculated with
uncloned SIVmne intrarectally (Polacino et al., 1999b). With
the exception of one time point for one animal (93080, week
177 after challenge), these macaques remained seronegative
by conventional ELISA at all times after challenge, including
the present study period (Table 1). By a sensitive Western
blot assay, we detected low levels of seroreactivity against
p27gag in sporadic samples from animals 93206 and 93080
and from animal 92175 after week 100 postchallenge (Pola-
cino et al., 1999b). These were the only 3 animals of the 34
unimmunized control macaques that exhibited this serolog-
ical pattern following SIVmne challenge, although the other
31 animals all seroconverted by standard assays after infec-
tion. This phenomenon was also reported in monkeys with
transient viremia after challenge with other SIV strains
including SIVmac251 (Dittmar et al., 1995; McChesney et
al., 1998; Miller et al., 1994; Pauza et al., 1993; Trivedi et al.,
1996; van Rompay et al., 1998). As shown in Fig. 2C, all
three unimmunized LLSI macaques were infected with
E11S-like major variants, although one macaque (#93206)
was infected largely with a variant that contained a single
nucleotide mutation that lead to a valine to isoleucine
substitution at position 10 of the sequenced region, which
persisted and dominated during the later course of SIV
infection in this animal. SIV sequences remained homoge-
neous in all three macaques for 226 weeks (Fig. 2C). The
rates of SIV sequence evolution were 0.008%/site/year in
macaque 93080, 0.006% in macaque 93206, and 0.006%
in macaque 92175; all were not different from zero (Table 3).
The average evolutionary rate of SIV sequences in these
unimmunized LLSI macaques was 0.003%/site/year,
which was not different from zero (P = 0.71) and was
consistent with findings in vaccinated LLSI macaques.
Sequence diversity in a macaque with delayed disease
progression
In macaque 91272 who had a delayed progression of
diseases, SIV DNA remained at low levels between weeks 2
(47.8 copies/106 PBMC) and 44 (44.5 copies/106 PBMC),
and rebounded to 7691 copies/106 PBMC at week 99 which
was 2 weeks before this macaque died from simian AIDS
(Fig. 1). Interestingly, SIV V1 sequences changed continu-
ously and accumulated as viral load increased during the 99-
week period of study (Fig. 2D). SIV sequences remained the
same as the challenged virus, clone E11S, at week 2 post
inoculation, and started evolving slightly at week 44, and
significantly at week 99. The evolution rate of SIV sequen-
Fig. 2. Deduced amino acid sequence alignment of SIV env V1 regions from LLSI macaques. All sequences are aligned with the consensus sequences from
SIVmne. Dots indicate identical sequences; dashes denote deletion. Time (weeks) was after virus challenge as described in Table 1 (Polacino et al., 1999a,
1999b, 1999c). Animals # 91250, #91263, and #92175 were virus negative at all time tested for 1 or 2 years after the first challenge with E11S by
intravenous (IV) route, and then were challenged again intravenously (animals # 91250, #91263) or intrarectally (#92175) with uncloned SIVmne. The
sampling time (in weeks) for these three animals was after the second challenge.
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significantly higher than those in both vaccinated and
unimmunized LLSI macaques (P < 0.0001). The significant
sequence variation of SIV in this macaque was comparable
to those in macaques with progressive infection of SIVmne
(Overbaugh et al., 1991).
Detection of SIV RNA in blood plasma obtained at late
infection of LLSI macaque by ultrasensitive RT-PCR assays
SIV sequence changes accumulate as a result of complet-
ed rounds of viral replication in vivo. The lack of viralevolution in LLSI macaques would indicate undetectable to
low levels of viral replication in vivo that did not result in
variation of SIV V1 sequences. To further determine whether
there was residual viral replication in these LLSI macaques,
we applied a sensitive RT-PCR to assess SIV RNA in blood
plasma specimens that were SIV RNA negative by conven-
tional RT-PCR (Polacino et al., 1999a, 1999b, 1999c). We
focused on plasma samples obtained at the last time points
from each study macaque because detectable plasma virus at
late infection would indicate on-going production of SIV in
vivo. A low level of plasma viremia was detected from one
(#91250) out of seven LLSI macaques, only by performing
Table 3
Analysis of the evolution rate of SIVmne V1 region in macaques with
persistently low levels of SIV infection (LLSI)
Animal Rate
(%/site/year)
95% CI P valuea
Immunized LLSI macaques
90114 0.001  0.007 0.010 0.7244
91263  0.019  0.050 0.012 0.2255
91250 0.058 0.049 0.068 < 0.0001
Unimmunized LLSI macaques
93206  0.006  0.014 0.002 0.1700
92175 0.006  0.021 0.033 0.6685
93080  0.008  0.027 0.012 0.4270
Vaccinated macaque with delayed disease progression
91272 1.178 1.073 1.283 < 0.0001
a The evolution rate of SIV V1 sequences in each animal was compared to
zero. A P value equal to or less than 0.05 indicates significant difference
from zero, which suggests there is a significant evolution of SIV sequences
in the animal.
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sample. Interestingly, animal 91250 was the only LLSI
macaque with a low level of viral evolution (Table 3),
indicating a continued viral replication in this macaque.
We then compared SIV env V1 sequences from plasma with
proviral sequences obtained from PBMC. Overall, SIV V1
sequences in the plasma were very homogeneous (Fig. 2B).
Because the viral load was extremely low in sample avail-
able, we could not exclude the possibility that the homoge-
neous sequences were generated from a few viral RNA
templates. However, the viral sequences from plasma were
essentially identical to those in PBMC at the same time
point. By using the same RT-PCR system, we found hetero-
geneous sequence populations in the plasma obtained at
week 99 from macaque 91272 who progressed to simian
AIDS later (Fig. 2D). The sequences in this plasma were also
similar to sequences from PBMC at week 99 (Fig. 2D).Discussion
We demonstrated here that SIV DNA persisted in the
peripheral blood at extraordinarily low levels in most, if not
all, macaques that were previously reported to be transiently
viremic by conventional assays. The viral load in these LLSI
macaques was orders of magnitudes less than those of other
SIV-infected monkeys reported (Polacino et al., 1999a,
1999b, 1999c). The persistence of extremely low levels of
SIV infection was discovered only by performing extensive
PCR amplifications and sequence analyses. The viral loads
in these macaques were relatively higher early post viral
inoculation, but typically not detected thereafter by conven-
tional assays. These animals were termed ‘‘transiently
viremic macaques’’ because low frequencies of SIV in a
later infection precluded their detection by routine assays
(Dittmar et al., 1995; Miller et al., 1994; Pauza et al., 1993;Polacino et al., 1999a, 1999b; Trivedi et al., 1996; van
Rompay et al., 1998). Lack of SIV sequence evolution and
plasma viral RNA suggest an essential absence of virus
replication in most of these LLSI animals. However, detect-
able low levels of viral evolution and SIV RNA in blood
plasma at week 235 post infection of macaque 91250
indicate a residual viral replication, at least in this LLSI
animal. The LLSI macaques have remained free of SIV-
associated illness while having maintained low levels of
SIV infection, and are still alive even 10 years after virus
inoculation.
The mechanisms that account for the persistence of SIV
infection at such low levels are unclear. Several possible
explanations could be proposed. First, the low viral copy
numbers may be the result of exposure to a relatively less
infectious SIV either contained in the initial dose adminis-
tered to LLSI macaques or entered initially into LLSI
macaques, as compared to the infectious SIV that was
administered and entered into macaques with progressive
infection. In support of this possibility, transient infection or
occult systemic infection without seroconversion was large-
ly found in macaques challenged with low doses of SIV
(Dittmar et al., 1995; McChesney et al., 1998; Miller et al.,
1994; Pauza et al., 1993; Trivedi et al., 1996; van Rompay
et al., 1998). However, our study design of the same
infectious dose for all macaques would argue against this
hypothesis. Furthermore, in macaque 91272 who exhibited a
delayed progression of diseases, SIV DNA remained at
relatively low levels during weeks 2–44, but never declined
to the set point seen in LLSI macaques, then rebounded to
7691 copies/106 PBMC at week 99, 2 weeks before this
macaque died from simian AIDS. Thus, an initial low viral
load in early infection did not guarantee a controlled low
level of infection. Continuous viral decline to a set point
might be critical to lead to a contained low level of SIV
infection.
Second, SIV variants persisted in LLSI macaques
might be replication-defective or attenuated, so that the
animals remain free from any disease associated with SIV
infection (Marthas et al., 1989, 1993). The extreme
homogeneity of SIV sequences over the study period
and the failure to isolate infectious virus in vitro at late
time points are indicative of the hypothesis that the SIV
strains persisted in LLSI macaques might be attenuated.
The observation that macaques infected with E11s or
clone 8 (biological or molecular clones of SIVmne,
respectively) show recurring nef gene alterations (Hei-
decker et al., 1998) also supports this hypothesis. How-
ever, SIV variants in animal 91250 are unlikely
replication-defective because the viral evolution and the
detectable SIV virus in blood plasma at late time points
indicate ongoing viral replication and production. Contin-
uous follow-up on these macaques and further character-
ization of the whole genome of the SIV strain persisting
in these LLSI macaques would be warranted to further
demonstrate this possibility.
T. Zhu et al. / Virology 323 (2004) 208–219216Third, acquired immunity may contribute to the control
of SIV infection at low levels (Amara et al., 2001; Barouch
et al., 2000, 2002; Rose et al., 2001; Schmitz et al., 1999;
Shiver et al., 2002). In our studies, four LLSI macaques
were immunized before viral challenge. Macaque 91278,
despite having been vaccinated with preparations that
contained only SIVmne gag/pol, had CTL reactive to SIV
env at 12 and 24 weeks post SIV challenge as well as a weak
response to SIV gag/pol (Kent et al., 1996). The detection of
the CTL responses to SIV env proteins that were not
included in vaccine suggests that animals with such low
SIV infection may induce a cellular immune response
postchallenge. Neutralization antibodies to SIVmne were
detected at the time of virus challenge in three vaccinated
LLSI animals (macaques 91250, 91263, and 91278) and in
vaccinated macaque 91272 who progressed to simian AIDS,
but not in immunized macaque 90114 and the three unim-
munized macaques (Table 1) (Polacino et al., 1999a, 1999b,
1999c). The three unimmunized LLSI macaques were
essential seronegative, but only exhibited very low levels
of seroreactivity against p27gag by a sensitive Western blot
assay (Polacino et al., 1999b), as seen typically in the
transiently viremic macaques challenged with different
SIV strains (Dittmar et al., 1995; McChesney et al., 1998;
Miller et al., 1994; Pauza et al., 1993; Trivedi et al., 1996;
van Rompay et al., 1998). Whether these acquired immune
responses contributed to the control of SIV infection at such
levels below the detection of routine assays requires further
study to understand their functional relevance in this pattern
of SIV infection.
Furthermore, other factors including inheritance of ge-
netic defects and distinct MHC types (Dean et al., 1996;
Gonzalez et al., 2001; Huang et al., 1996; Liu et al., 1999;
MacDonald et al., 2000; Michael et al., 1997; Samson et al.,
1996) may contribute to the persistence of low levels of SIV
infection. Understanding the mechanisms that account for
the control of SIV infection at such low levels should be of
great interest to efforts to develop strategies for therapy and
immunization.Materials and methods
Limiting dilution PCR and RT-PCR to amplify SIV DNA in
PBMC and viral RNA in blood plasma below the detection
limit of conventional assays
Genomic DNA was isolated from PBMC, and SIV RNA
was extracted from blood plasma as described previously
(Polacino et al., 1999a, 1999b, 1999c; Zhu et al., 2002). RT,
limiting dilution PCR, and RT-PCR (Zhu et al., 2002) were
performed by using the Extend High Fidelity PCR System
(Roche Molecular Biochemicals) with the following primers
to amplify the variable region (V1) of SIV env: outer FF5
(position 6070–6096 of SIVmne sequence in the Los
Alamos Database, 5V-GTATGGGATGTCTTGGGAAT-CAGCTGC-3V) and FF8 (6753–6727, 5V-ATCGTAGGGT-
TATTACAAACAGTGTTC-3V); inner FF6 (6159–6184, 5V-
TATGGTGTACCAGCTTGGAGGAATGC-3V) and FF7
(6609–6582, 5V-AGAACAGAGAAAAATTGGGACAG-
TACAA-3V). PCR was performed with special procedures
to prevent contamination throughout the study as described
previously (Zhu et al., 2002, 2003). Positive controls for
PCR included genomic DNA containing 1, 4, 25, and 100
copies of SIV DNA. To avoid contamination between
samples, which was particularly important to this study
because of the similar challenge virus for every macaque,
we developed several procedures (Zhu et al., 2002, 2003). A
biosafety cabinet was placed in a ‘‘PCR-clean’’ room. The
room, hood, and equipment were decontaminated after each
use, one sample per day. Experiments with samples of each
macaque were separated by intervals of at least 2 weeks to
further avoid cross-contamination between samples. In each
experiment of limiting dilution PCR, SIV negative DNA
and reagent control (distilled water) were included in
duplicate. The PCR results would be rejected if any of the
negative controls were positive. PCR was sensitive to detect
one copy per Ag DNA or cDNA per reaction, and specific
for the detection of SIV (data not shown). SIV copy
numbers were calculated based on multiple independent
limiting dilution PCR on each sample (Zhu et al., 2002,
2003) and a computer program, ‘‘QUALITY’’, as described
previously (Rodrigo et al., 1997).
Cloning, sequencing, and sequence analyses
PCR products were cloned and sequenced as described
previously (Zhu et al., 2002). Clonal sequences (7–17) for
each specimen were obtained from several independent PCR
products amplified from 20 or more SIV templates. PCR
product amplified from one or two templates, based on the
calculation by limiting-dilution PCR and ‘‘QUALITY’’ as
described above, was cloned separately; only one clonal
sequence was included for sequence analyses to further avoid
resampling of the same virus template. Sequences were
aligned using Clustal W (Thompson et al., 1994). The most
recent common ancestor (MRCA) sequence for each of the
seven SIV infections was inferred using a maximum likeli-
hood estimation (MLE) phylogram constructed by PAUP*
(Sinauer Associate, Inc., Sunderland, MA). The model of
evolution (TVM+I) was selected using the AIC (Akaike,
1974) in Modeltest Version 3.06 (Posada and Crandall,
1998). Parameters of this model were: equilibrium nucleotide
frequencies: fA = 0.3899, fC = 0.1762, fG = 0.2106, fT =
0.2233; assumed proportion of invariable sites = 0.4799; R
matrix values: RA<–>C = 7.587, RA<–>G = RC<–>T = 26.361,
RA<–>T = 2.563, RC<–>G = 1.208, RG<–>T = 1. The genetic
distance from each subject sequence to the MRCA se-
quence was calculated using this model. The slope of the
regression equation of these distances against time of
sampling in years is the rate of divergence from the
MRCA.
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